Stocktoria
Maze Therapeutics, Inc. MAZE
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2025-01-31
Maze Therapeutics, Inc. statistics & valuation
Market cap$1.6B
P / B4.4×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 |
|---|---|---|
| Operating margin | — | 34.4% |
| Net margin | — | 31.2% |
| FCF margin | — | 44.7% |
| Return on assets | -33.0% | 21.7% |
| Return on equity | -36.9% | -16.8% |
| Current ratio | 15.50 | 9.76 |
Source: SEC EDGAR filings · CIK 0001842295 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.